NCT03066661No Longer Available不适用
Expanded Access to Entrectinib (RXDX-101) for the Treatment of Cancers With NTRK, ROS1, or ALK Gene Fusions
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 试验地点
- 1
研究概览
简要总结
Expanded access to entrectinib will be given to patients with cancers harboring NTRK1/2/3, ROS1, or ALK gene fusions who do not qualify for participation in, or who are otherwise unable to access, an ongoing clinical trial for entrectinib.
研究设计
- 研究类型
- Expanded Access
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of advanced cancer with an NTRK1, NTRK2, NTRK3, ROS1, or ALK gene fusion
- •Unable to participate in an ongoing entrectinib (RXDX-101) clinical trial
- •Willing and able to provide written, signed informed consent
- •Medically suitable for treatment with entrectinib (RXDX-101)
排除标准
- •Currently enrolled in an ongoing clinical study with any other investigational agent
研究者
研究点 (1)
Loading locations...
相似试验
Approved For Marketing
不适用
Expanded Access to Provide Larotrectinib for the Treatment of Cancers With a NTRK Gene FusionTumors Harboring NTRK FusionNCT03025360Bayer
已完成
1 期
Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations.Locally Advanced Solid TumorsMetastatic Solid TumorsNCT02097810Hoffmann-La Roche84
No Longer Available
不适用
Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene FusionSolid Tumors Harboring NTRK FusionNCT03206931Bayer
No Longer Available
不适用
Expanded Access to RXDX-105 for Cancers With RET AlterationsCancers With RET AlterationsNCT03052569Hoffmann-La Roche
Approved For Marketing
不适用
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) ActivationNon Small Cell Lung CancerMedullary Thyroid CancerPapillary Thyroid CancerOther Solid Tumors With Evidence of Activating RET AlterationBreast CancerPancreatic CancerColon CancerNCT03906331Eli Lilly and Company